Eisai and Biogen's Alzheimer's therapy Leqembi will be priced at $26,500 per year – a little less than misfired predecessor Aduhelm – after getting conditional authorisation for the drug from ...

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...

The new findings center on a subset of 22 participants who received amyloid-removing drugs the longest, on average eight years. Long-term amyloid removal cut in half their risk of symptom onset, ...

As a result, participants receiving gantenerumab in DIAN-TU OLE were switched to Eisai and Biogen’s anti-amyloid therapy Leqembi (lecanemab). Another study, the DIAN-TU-002 trial (NCT06647498), has ...

This initiative is in compliance with European Regulation 2016/161, which establishes detailed rules regarding the safety features displayed on the packaging of medicines for human use.

After hours: March 19 at 4:05:13 PM EDT Loading Chart for GPK ...

After hours: March 21 at 7:27:47 PM EDT Loading Chart for BIIB ...

Soon-to-be medical school graduates received 877 more primary care position offers in the 2025 Main Residency Match compared with the previous year, according to the National Resident Matching ...